Elon Musk's Neuralink Receives Approval for Brain Chip Trials in Canada
Canada's University Health Network partners with Neuralink for brain chip trials. Neuralink receives approval from Health Canada for clinical trials in the country. Focus on patients with Quadriplegia due to ALS and spinal cord injury.
UHN's chief executive, Kevin Smith, expressed pride in leading the research advancement in neurosurgery. While UHN will be the exclusive trial site in Canada, the start date has not been disclosed.
Neuralink recently confirmed regulatory approval from Health Canada to commence clinical trials in the country. The company shared the news on X, a social media platform owned by Musk, stating, "Health Canada has approved the launch of our first clinical trial in Canada! Recruitment is now open." Neuralink is specifically looking for patients with Quadriplegia due to ALS or spinal cord injury.
Neuralink has been actively recruiting patients in the U.S., U.K., and Canada, directing interested individuals to a registry on its website. Competitors like Synchron Inc. are also gearing up for their own upcoming trials.
The primary focus of Neuralink's initial product is to enable patients to control external devices, such as computers, using their thoughts. While the company is also exploring treatments for conditions like blindness, those projects are still in the pipeline.
Elon Musk envisions a future where Neuralink could collaborate with healthy individuals to enhance functions like memory.
Earlier this year, the company implanted its device in its first human patient, Noland Arbaugh, at the Barrow Neurological Institute in Phoenix.
Canada's University Health Network partners with Neuralink for brain chip trials
Neuralink receives approval from Health Canada for clinical trials in the country
Focus on patients with Quadriplegia due to ALS and spinal cord injury
Source: FINANCIAL POST